Follow the NKGen Biotech, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 2 June 2025 (Acquisition). Among the most active insiders: Song Paul Y.. The full history is openly available.
12
Insider Decl.
n/a
Thresholds
€5m
8 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NKGen Biotech, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
45Σ signal
Buys €5mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
NKGen Biotech, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias basadas en células NK para el tratamiento del cáncer. Cotiza en el NASDAQ bajo el ticker NK.